Home

Health Care

Honoring Industrial Innovation: BIO to Award 3rd Carver

Biotechnology might seem like a new science to many, but it has its roots in the work of some early big thinkers — among them George Washington Carver, arguably one of the world’s first industrial biotechnologists and the father of sustainable farming.

Rare Diseases: Can We Speed Treatments?
Battle Joined: Knowledge Pool Created to Fight Neglected Diseases

Scientific discoveries happen when researchers collaborate. That’s the thinking behind a partnership formed by GlaxoSmithKline and Alnylam Pharmaceuticals to share intellectual property (IP) and industrial know-how to develop new therapies to treat the world’s most neglected tropical diseases.

Millions Around World to Observe Rare Disease Day

On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS).

XENOTRANSPLANTATION: The Benefits and Risks of Special Organ Transplantation

Human organ transplantation is a relatively new field of medicine that is now facing a significant challenge.

From Biotech to Box Office: Film Draws from Real-Life Story

Real life sometimes looms larger than the characters and storylines of Hollywood.

Intellectual Property Pool: Podcast with BVGH, Alnylam and GlaxoSmithKline

GlaxoSmithKline and Alnylam Pharmaceuticals recently announced that BIO Ventures for Global Health will administer the Intellectual Property (IP) Pool to aid in the discovery and development of new treatments for neglected tropical diseases.

BioBytes: Genetically Engineered Animals

Disease resistant animals, environmentally friendly livestock, pharmaceuticals produced by goats - are these really possible?

Biotechnology: Toward a Sustainable Future

Sustainable development is no small undertaking for international companies looking to meet today’s energy, food and environmental needs without compromising the Earth’s resources or its future. The innovative solution these corporate leaders are turning to is biotechnology, whether it’s to augment agricultural productivity, reduce greenhouse gas emissions, create an innovative disease therapy or diminish the use of pesticides.

Health Care Reform: Biotech Industry Supports Universal Access to Health Care

With the Senate no longer filibuster-proof, the future of the health care bill is fairly murky. In early January, Congress was deep into negotiations on a final version, which includes language that would be a major shot in the arm for the biotechnology industry and provide great benefits to patients.

The Next Big Thing: Targeted Treatments

Personalized medicine involves using the advanced tools of molecular genetics and diagnostics to predict how patients will respond to drugs, reducing harmful side effects and increasing benefit. In addition, the panoply of technologies enabling this revolution in medicine can produce a personal medical profile that can guide the physician toward selecting the most appropriate drug or treatment regimen and help individuals stave off diseases before they manifest themselves. This dual combination of diagnostic and treatment technologies is at the heart of personalized medicine and is poised to transform healthcare dramatically.

10 to Watch: Hot Biotech Prospects

Technological innovation promises to redefine health care as we know it.

BioBytes: Biotechnology and Vaccines

New vaccines employing biotech innovations are changing the way we prevent illness.

Biotech is Still Golden in the Golden State

We all know that California has been hit hard by the current recession. Sadly most of the state is facing dire economic realities that go much deeper than that.  However, its status as the world’s undisputed epicenter of biotechnology has not been tarnished one bit, according to a new survey released by the California Healthcare Institute.

Podcast with Dr. David Agus

Letters, Testimony & Comments

BIO’s comments on the Centers for Medicare and Medicaid Services’ (CMS) draft 2014 Call Letter
March 1 2013
  BIO’s comments on the Centers for Medicare and Medicaid Services’ (CMS) draft 2014 Call Letter, submitted Friday,...
SMU: BIO Comments on Creating an Alternative Approval Pathway for Certain Drugs to Address Unmet Medical Need
March 1 2013
  The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit...
Cell and Gene Therapy: BIO Comments on Preclinical Assessment of Investigational Cellular and Gene Therapy Products
February 27 2013
    Dear Sir/Madam:    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration...
Medicaid, Children’s Health Insurance Programs, and Exchanges
February 21 2013
Ms. Marilyn Tavenner, B.S.N., M.H.A. Acting Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H....
Electronic Submissions: BIO Comments on Providing Submissions in Electronic Format
February 19 2013
    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand Access
June 28 2012
  Pleased to move forward on biosimilars pathway Washington, D.C. (June 28, 2012) –Biotechnology...
More Press Releases →